<DOC>
	<DOCNO>NCT01822886</DOCNO>
	<brief_summary>Pilot clinical trial - Phase 2a , multicenter , single arm , open label trial - evaluate efficacy safety concomitant combination treatment Gemcitabine Romidepsin ( GEMRO ) regimen salvage treatment relapsed/refractory PTCL select population patient . Objectives focus preliminary dose-response , type patient , frequency dosing , safety tolerability profile .</brief_summary>
	<brief_title>Phase II Study Gemcitabine+Romidepsin Relapsed/Refractory Peripheral T-cell Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Patients histological diagnosis PTCL accord WHO classification Age ≥ 18 year Relapsed ( ≥1 ) refractory conventional chemotherapy/radiotherapy Stage IIV accord Ann Arbor stag System ECOG Performance status ≤2 Normal renal hepatic function Laboratory test result follow : Serum creatinine ≥ 2.0 mg/dL Total bilirubin ≥ 1.5 mg/dL AST ( SGOT ) ALT ( SGPT ) £2 x ULN £5 x ULN hepatic metastasis present Negative HIV HCV HBV status Adequate bone marrow reserve : Platelet count &gt; 100X109 cells/L platelet count &lt; 75X109 cells/L bone marrow disease involvement , absolute neutrophile count ( ANC ) &gt; 1,5 X109 , hemoglobin &gt; 8 g/dl . Able adhere study visit schedule protocol requirement Cardiac ejection fraction ( MUGA scan echocardiography ) &gt; 45 % Life expectancy &gt; 6 month Females childbearing potential ( FCBP ) must negative serum urine βhCG pregnancy test result within 7 day prior first dose study drug . Females nonchildbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy Both females childbearing potential male partner childbearing potential must agree use effective contraceptive method study 30 day last dose study drug . Measurable disease least 2 cm detect CT scan , assessed site radiologist Patients legally authorize representative must provide write informed consent Any serious active disease comorbid medical condition ( accord investigator 's decision ) Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Patients congenital long QT syndrome , history significant cardiovascular disease and/or take drug lead significant QT prolongation Corrected QT interval &gt; 480 msec ( use Fredericia formula ) Low K+ ( &lt; 3.8 mmol/L ) low Mg+ ( &lt; 0.85 mmol/L ) level , except correct begin chemotherapy Pregnant lactating female men woman childbearing potential willing use adequate method birth control duration study Previous exposure romidepsin gemcitabine CNS disease ( meningeal and/or brain involvement lymphoma ) testicular involvement History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance Active opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>T-cell lymphoma</keyword>
	<keyword>Romidepsin</keyword>
</DOC>